Sren Kjrulff - ChemoMetec Head RD
| CHY Stock | EUR 63.75 0.50 0.79% |
Insider
Sren Kjrulff is Head RD of ChemoMetec AS
| Phone | 45 48 13 10 20 |
| Web | https://chemometec.com |
ChemoMetec Management Efficiency
The company has return on total asset (ROA) of 0.3117 % which means that it generated a profit of $0.3117 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.4858 %, meaning that it generated $0.4858 on every $100 dollars invested by stockholders. ChemoMetec's management efficiency ratios could be used to measure how well ChemoMetec manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Sean OConnor | Teledyne Technologies Incorpora | 58 | |
| Leah Lambertson | Trimble | N/A | |
| Jason Connell | Teledyne Technologies Incorpora | 47 | |
| David Barnes | Trimble | 61 | |
| Susan Main | Teledyne Technologies Incorpora | 64 | |
| Eric Taranto | MKS Instruments | 55 | |
| Padmaprakash Iyer | Trimble | N/A | |
| Shaun Callaghan | Trimble | N/A | |
| Jaime Nielsen | Trimble | N/A | |
| Kathleen Burke | MKS Instruments | 58 | |
| Mark Gitin | MKS Instruments | 56 | |
| Jason VanWees | Teledyne Technologies Incorpora | 51 | |
| John Lee | MKS Instruments | 60 | |
| Robert Mehrabian | Teledyne Technologies Incorpora | 82 | |
| Seth Bagshaw | MKS Instruments | 63 | |
| Maryann Naddy | MKS Instruments | N/A | |
| David Henry | MKS Instruments | 51 | |
| David Ryzhik | MKS Instruments | N/A | |
| Melanie Cibik | Teledyne Technologies Incorpora | 63 | |
| Jennifer Reilly | MKS Instruments | N/A | |
| Janice Hess | Teledyne Technologies Incorpora | 63 | |
Management Performance
| Return On Equity | 0.49 | |||
| Return On Asset | 0.31 |
ChemoMetec AS Leadership Team
Elected by the shareholders, the ChemoMetec's board of directors comprises two types of representatives: ChemoMetec inside directors who are chosen from within the company, and outside directors, selected externally and held independent of ChemoMetec. The board's role is to monitor ChemoMetec's management team and ensure that shareholders' interests are well served. ChemoMetec's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, ChemoMetec's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Martin Behrens, Chief US | ||
| Christopher MSc, VP US | ||
| Michael Packert, Head Production | ||
| Steen Sondergaard, Chief Officer | ||
| Hans Glensbjerg, Vice COO | ||
| Lisbet Helles, Head Marketing | ||
| Sren Kjrulff, Head RD | ||
| Niels Nielsen, Chief Officer |
ChemoMetec Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is ChemoMetec a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.49 | |||
| Return On Asset | 0.31 | |||
| Profit Margin | 0.39 % | |||
| Operating Margin | 0.50 % | |||
| Current Valuation | 1.93 B | |||
| Shares Outstanding | 17.4 M | |||
| Shares Owned By Insiders | 10.87 % | |||
| Shares Owned By Institutions | 51.35 % | |||
| Price To Earning | 221.15 X | |||
| Price To Book | 40.66 X |
Currently Active Assets on Macroaxis
Other Information on Investing in ChemoMetec Stock
ChemoMetec financial ratios help investors to determine whether ChemoMetec Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in ChemoMetec with respect to the benefits of owning ChemoMetec security.